The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…
SER-252 enters Cohort 2 with blinded early observations that support the central premise: sustained delivery of a proven Parkinson’s medicine may be far more valuable when it asks less of patients and caregivers.
In biotechnology, there are moonshots, and then there are…
Many entered the week bracing for a Federal Reserve rate hike, yet the more constructive takeaway may be that policy makers still have room to choose patience. That possibility, alongside fresh evidence of AI-led ecommerce change, government-scale digital-health demand and advancing biotech milestones,…
